Cantex Pharmaceuticals is focused on developing azeliragon, a novel oral medication that acts as an antagonist of the RAGE (receptor for advanced glycation endproducts). This investigational drug is currently in Phase 2/3 clinical development and is designed to target various cancers, including glioblastoma, metastatic brain tumors, pancreatic cancer, and breast cancer, as well as to prevent acute kidney injury in hospitalized patients with pneumonia. Azeliragon works by inhibiting the interactions between RAGE and its natural ligands, such as HMGB1 and S100 proteins, which are known to promote cancer progression and metastasis. The drug has demonstrated a high level of safety and tolerability in clinical trials involving over 2,000 patients, with extensive preclinical evidence supporting its efficacy in reducing tumor growth and metastasis.

The mechanism of action of azeliragon is centered on blocking the overactivation of the RAGE receptor, which is associated with increased cancer growth and resistance to treatment. By inhibiting RAGE, azeliragon aims to disrupt the intracellular signaling pathways that facilitate cancer invasion and metastasis. The drug has received orphan drug designation for glioblastoma, providing it with seven years of protection from generic competition, and it is backed by several issued patents that secure its composition of matter until at least May 2034. Overall, Cantex Pharmaceuticals is leveraging the unique properties of azeliragon to address significant unmet medical needs in oncology and related fields.

United States

Cantex Pharmaceuticals, Inc. is a pharmaceutical company developing  treatments of cancer, complications of COVID-19 infection, and pulmonary inflammatory diseases.

Cantex Pharmaceuticals

Company Details